GILD实时信号 | 通过Getagraph.com最大化利润

出售 4099 min ago

@ $65.75

发出时间: 27 Apr 2024 @ 02:36

回报率: 1.10%

上一信号: Apr 26 - 22:48

上一信号: 购买

回报率: 1.07 %

Live Chart Being Loaded With Signals

Commentary (29 Apr 2024 @ 22:55):

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally...

Stats
今日成交量	1.68M
平均成交量	7.44M
市值	82.88B
EPS	$0 ( 2024-04-25 )
Last Dividend	$0.750 ( 2023-12-14 )
Next Dividend	$0 ( N/A )
P/E	14.77
ATR14	$1.615 (2.43%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-25	Telman Deborah H	Sell	515	Restricted Stock Unit
2024-04-25	Telman Deborah H	Buy	515	Common Stock
2024-04-25	Telman Deborah H	Sell	158	Common Stock
2024-04-01	Parsey Merdad	Sell	2 000	Common Stock
2024-03-28	Lofton Kevin E	Buy	34	Phantom Stock

INSIDER POWER
62.13
Last 99 transactions
Buy: 1 291 503 \| Sell: 311 301

音量相关性

長: -0.49 (neutral)

短: 0.25 (neutral)

Signal:(41) Neutral

Gilead Sciences Inc 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Gilead Sciences Inc 相关性 - 货币/商品

-0.56
( weak negative )

0.29
( neutral )

0.00
( neutral )

-0.22
( neutral )

0.32
( neutral )

0.56
( weak )

Gilead Sciences Inc 财务报表

Annual	2023
营收:	$27.12B
毛利润:	$21.15B (77.99 %)
EPS:	$4.54

FY	2023
营收:	$27.12B
毛利润:	$21.15B (77.99 %)
EPS:	$4.54

FY	2022
营收:	$27.28B
毛利润:	$21.62B (79.26 %)
EPS:	$3.66

FY	2021
营收:	$27.31B
毛利润:	$20.70B (75.82 %)
EPS:	$4.96

Financial Reports:

No articles found.

Gilead Sciences Inc Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0.730 (N/A)	$0.730 (N/A)	$0.750 (N/A)	$0.750 (N/A)	$0.750 (N/A)	$0.750 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Gilead Sciences Inc Dividend Information - Dividend Knight

Dividend Sustainability Score: 5.47 - average (49.38%) | Divividend Growth Potential Score: 6.34 - Stable (26.81%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	$0.430	2015-06-12
Last Dividend	$0.750	2023-12-14
Next Dividend	$0	N/A
Payout Date	2023-12-28
Next Payout Date	N/A
# dividends	35	--
Total Paid Out	$21.49	--
Avg. Dividend % Per Year	2.65%	--
Score	4.68	--
Div. Sustainability Score	5.47
Div.Growth Potential Score	6.34
Div. Directional Score	5.90	--

Next Divdend (Est)
(2024-07-01)

$0.764 Estimate 39.70 %

Dividend Stability

0.79 Good

Dividend Score

4.68

Pay Frequency

Quarterly

Yearly Payout

Year	Amount	Yield
2015	$1.290	1.36%
2016	$1.840	1.88%
2017	$2.08	2.80%
2018	$2.28	3.08%
2019	$2.52	3.97%
2020	$2.72	4.17%
2021	$2.84	4.72%
2022	$2.92	4.02%
2023	$3.00	3.51%
2024	$0	0.00%

Dividend Commentary

With a moderate Dividend Sustainability Score (DSS), the company may sustain its dividends, but continuous monitoring is advised for any financial shifts. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.

Top 10 dividend Companies for NASDAQ

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
PSEC	Dividend Royal	2023-12-26	Monthly	21	7.04%	8.50
SLVO	Dividend Royal	2023-11-20	Monthly	12	10.77%	8.50
QYLD	Dividend Royal	2023-11-20	Monthly	11	7.50%	8.50
GAIN	Dividend Royal	2023-12-04	Monthly	20	8.19%	8.50
GLDI	Dividend Royal	2023-11-20	Monthly	12	7.15%	8.50
OXLC	Dividend Royal	2023-12-14	Monthly	14	10.00%	8.50
OXSQ	Dividend Diamond	2023-12-14	Monthly	21	9.10%	8.50
HRZN	Dividend King	2023-12-18	Monthly	15	6.60%	8.45
USOI	Dividend Royal	2023-11-20	Monthly	8	16.70%	8.28
PFLT	Dividend King	2023-11-15	Monthly	14	6.50%	8.27

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.0176	1.500	9.65	10.00	[0 - 0.5]
returnOnAssetsTTM	0.00860	1.200	9.71	10.00	[0 - 0.3]
returnOnEquityTTM	0.0232	1.500	-0.854	-1.280	[0.1 - 1]
payoutRatioTTM	5.87	-1.000	10.00	-10.00	[0 - 1]
currentRatioTTM	0.980	0.800	-0.102	-0.0814	[1 - 3]
quickRatioTTM	0.721	0.800	-0.463	-0.371	[0.8 - 2.5]
cashRatioTTM	0	1.500	-1.111	-1.667	[0.2 - 2]
debtRatioTTM	0	-1.500	0	0	[0 - 0.6]
interestCoverageTTM	9.53	1.000	7.58	7.58	[3 - 30]
operatingCashFlowPerShareTTM	6.80	2.00	7.73	10.00	[0 - 30]
freeCashFlowPerShareTTM	6.42	2.00	6.79	10.00	[0 - 20]
debtEquityRatioTTM	0	-1.500	0	0	[0 - 2.5]
grossProfitMarginTTM	0.777	1.000	0.382	0.382	[0.2 - 0.8]
operatingProfitMarginTTM	0.336	1.000	5.28	5.28	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0	1.000	-1.111	-1.111	[0.2 - 2]
assetTurnoverTTM	0.488	0.800	-0.0824	-0.0659	[0.5 - 2]
Total Score				5.47

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	168.55	1.000	10.00	0	[1 - 100]
returnOnEquityTTM	0.0232	2.50	-0.549	-1.280	[0.1 - 1.5]
freeCashFlowPerShareTTM	6.42	2.00	7.86	10.00	[0 - 30]
dividendYielPercentageTTM	4.62	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	6.80	2.00	7.73	10.00	[0 - 30]
payoutRatioTTM	5.87	1.500	10.00	-10.00	[0 - 1]
pegRatioTTM	0.570	1.500	9.53	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.309	1.000	4.78	0	[0.1 - 0.5]
Total Score				6.34

Gilead Sciences Inc

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.